We are live on
!
Find out more
Axa Portfolio holdings
AUM
$91.9M
1-Year Est. Return
27.41%
This Fund
S&P 500
This Quarter
Est. Return
+0.74%
1 Year Est. Return
+27.41%
3 Year Est. Return
+100.68%
5 Year Est. Return
+129.89%
10 Year Est. Return
+554.73%
AUM
$35.6B
AUM Growth
+$166M
(+0.47%)
Cap. Flow
+$350M
Cap. Flow
% of AUM
0.98%
Top 10 Holdings %
Top 10 Hldgs %
19.85%
Holding
1,363
New
118
Increased
473
Reduced
442
Closed
143
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AT&T
T
|
+$76.2M |
| 2 |
S&P Global
SPGI
|
+$73M |
| 3 |
Adobe
ADBE
|
+$62.1M |
| 4 |
Bristol-Myers Squibb
BMY
|
+$56.5M |
| 5 |
NVIDIA
NVDA
|
+$52.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
BNY
Bank of New York Mellon
BNY
|
+$60.1M |
| 2 |
Colgate-Palmolive
CL
|
+$57.1M |
| 3 |
Cisco
CSCO
|
+$55.2M |
| 4 |
Generac Holdings
GNRC
|
+$44.8M |
| 5 |
Alibaba
BABA
|
+$42.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 30.95% |
| 2 | Healthcare | 17.81% |
| 3 | Consumer Discretionary | 11.77% |
| 4 | Financials | 10.45% |
| 5 | Industrials | 7.79% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
501
Sarepta Therapeutics
SRPT
$2.13B
| $9.1M | 0.03% |
98,407
+3,617
| +4% | +$279K |
|
502
Magna International
MGA
$17.2B
| $9.1M | 0.03% |
120,889
+16,931
| +16% | +$1.39M |
|
503
TD Synnex
SNX
$21.2B
| $9.08M | 0.03% |
+87,200
| New | +$10.4M |
|
504
iShares Core S&P 500 ETF
IVV
$839B
| $9.06M | 0.03% |
21,031
+1,079
| +5% | +$478K |
|
505
Dominion Energy
D
$56.4B
| $9.05M | 0.03% |
123,950
-32,216
| -21% | -$2.46M |
|
|
ENV
506
DELISTED
ENVESTNET, INC.
ENV
| $9.01M | 0.03% |
112,220
-126,247
| -53% | -$9.65M |
|
|
KRTX
507
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $9M | 0.03% |
73,582
+2,709
| +4% | +$313K |
|
508
Clean Harbors
CLH
$17.1B
| $8.94M | 0.03% |
86,100
-2,600
| -3% | -$256K |
|
509
Lennox International
LII
$12.6B
| $8.94M | 0.03% |
30,400
| – | – |
|
510
Envista
NVST
$4.08B
| $8.92M | 0.03% |
213,300
+109,700
| +106% | +$4.63M |
|
511
Wintrust Financial
WTFC
$10.2B
| $8.85M | 0.02% |
110,100
-1,000
| -0.9% | -$73.8K |
|
512
Everest Group
EG
$14.6B
| $8.84M | 0.02% |
+35,264
| New | +$9.04M |
|
513
Celldex Therapeutics
CLDX
$3.05B
| $8.8M | 0.02% |
162,983
-65,968
| -29% | -$3.1M |
|
514
Zentalis Pharmaceuticals
ZNTL
$290M
| $8.78M | 0.02% |
131,801
+4,856
| +4% | +$280K |
|
|
VMRK
515
Vivmark Residential
VMRK
$49.7B
| $8.73M | 0.02% |
107,842
+257
| +0.2% | +$21.2K |
|
516
CrowdStrike
CRWD
$248B
| $8.69M | 0.02% |
141,416
-7,060
| -5% | -$455K |
|
517
Crane NXT
CXT
$2.77B
| $8.63M | 0.02% |
261,989
-45,200
| -15% | -$1.51M |
|
518
First Citizens BancShares
FCNCA
$24.2B
| $8.6M | 0.02% |
10,200
+9,700
| +1,940% | +$8.06M |
|
519
LKQ Corp
LKQ
$5.96B
| $8.6M | 0.02% |
170,914
-20,368
| -11% | -$1.04M |
|
520
Centene
CNC
$33.2B
| $8.59M | 0.02% |
137,846
+41,178
| +43% | +$2.75M |
|
521
Dow Inc
DOW
$21.9B
| $8.55M | 0.02% |
148,472
+21,582
| +17% | +$1.32M |
|
|
NGM
522
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
| $8.52M | 0.02% |
405,367
+112,926
| +39% | +$2.49M |
|
523
PNC Financial Services
PNC
$94.8B
| $8.38M | 0.02% |
42,855
-3,607
| -8% | -$681K |
|
|
BCYC
524
Bicycle Therapeutics
BCYC
$255M
| $8.26M | 0.02% |
198,673
+1,163
| +0.6% | +$40.7K |
|
525
ALX Oncology
ALXO
$250M
| $8.16M | 0.02% |
110,493
+4,071
| +4% | +$271K |
|
Similar funds
VI
FA
PBCM
CCAM
GBA
AWP
HI
DCA
Axa's Q3 2021 Portfolio in Review
As of Q3 2021, Axa held 1,363 positions worth $35.6B, up 0.47% from $35.5B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
Axa's Q3 2021 filing shows 118 new, 473 increased, 442 reduced and 143 closed positions. Its largest new stake was GXO Logistics: 575,960 shares worth $45.2M. The largest sale was Bank of New York Mellon, an estimated $60.1M.
By sector, the portfolio is most concentrated in Technology at 31% of assets, up from 30% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Axa's largest Q3 2021 buy was GXO Logistics: 575,960 shares worth $45.2M.
- Axa added most to AT&T in Q3 2021, an estimated $76.2M increase.
- Axa's biggest Q3 2021 reduction was Bank of New York Mellon, cutting an estimated $60.1M.
- Axa fully exited Proofpoint, Inc. in Q3 2021, selling an estimated $35.3M.
- Axa's ten largest holdings make up 20% of its $35.6B portfolio in Q3 2021.
- Axa opened 118 new positions and closed 143 in Q3 2021.
- Axa's portfolio value rose 0.47% quarter-over-quarter to $35.6B.
Based on Axa's 13F filing for Q3 2021, filed 15 Nov 2021.